Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark A Exley

Showing results (21-30 of 71) with videos related to

Pageof 8
Sort By:
Cancer Research|December 6, 2006
Hyporesponsiveness to natural killer T-cell ligand alpha-galactosylceramide in cancer-bearing state mediated by CD11b+ Gr-1+ cells producing nitric oxideKazuhiko Yanagisawa, Mark A Exley, Xiaofeng Jiang, et al.
Plos One|March 31, 2010
Paucity of CD4+ natural killer T (NKT) lymphocytes in sooty mangabeys is associated with lack of NKT cell depletion after SIV infectionNamita Rout, James G Else, Simon Yue, et al.
Journal of Neuro-Oncology|November 28, 2023
Targeted immunotherapy for glioblastoma involving whole tumor-derived autologous cells in the upfront setting after craniotomyCarrie E Andrews, Jenny Zilberberg, Raul Perez-Olle, et al.
Nature Reviews. Rheumatology|September 3, 2016
What rheumatologists need to know about innate lymphocytesMark A Exley, George C Tsokos, Kingston H G Mills, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 7, 2009
CD1d activation and blockade: a new antitumor strategyMichele W L Teng, Simon Yue, Janelle Sharkey, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 22, 2009
CD1d-based combination therapy eradicates established tumors in miceMichele W L Teng, Janelle Sharkey, Nicole M McLaughlin, et al.
European Journal of Immunology|December 30, 2009
The A2aR adenosine receptor controls cytokine production in iNKT cellsMichael Nowak, Lydia Lynch, Simon Yue, et al.
Frontiers in Immunology|October 10, 2018
Positive & Negative Roles of Innate Effector Cells in Controlling Cancer ProgressionDorian Stolk, Hans J van der Vliet, Tanja D de Gruijl, et al.
Frontiers in Immunology|May 8, 2026
Physiological, patho-physiological, and potential therapeutic roles for neutrophils in cancer & beyondConnor McGarrity-Cottrell, Aoife McGinley, Natalia Becares, et al.
Clinical Immunology (Orlando, Fla.)|June 2, 2019
Evaluation of the frequency of invariant natural killer T (iNKT) cells in nasal polypsMohammad Fereidouni, Afshin Derakhshani, Simon Yue, et al.
Pageof 8

Showing results (21-30 of 71) with videos related to

Sort By:
Pageof 8
Cancer Research|December 6, 2006
Hyporesponsiveness to natural killer T-cell ligand alpha-galactosylceramide in cancer-bearing state mediated by CD11b+ Gr-1+ cells producing nitric oxideKazuhiko Yanagisawa, Mark A Exley, Xiaofeng Jiang, et al.
Plos One|March 31, 2010
Paucity of CD4+ natural killer T (NKT) lymphocytes in sooty mangabeys is associated with lack of NKT cell depletion after SIV infectionNamita Rout, James G Else, Simon Yue, et al.
Journal of Neuro-Oncology|November 28, 2023
Targeted immunotherapy for glioblastoma involving whole tumor-derived autologous cells in the upfront setting after craniotomyCarrie E Andrews, Jenny Zilberberg, Raul Perez-Olle, et al.
Nature Reviews. Rheumatology|September 3, 2016
What rheumatologists need to know about innate lymphocytesMark A Exley, George C Tsokos, Kingston H G Mills, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 7, 2009
CD1d activation and blockade: a new antitumor strategyMichele W L Teng, Simon Yue, Janelle Sharkey, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 22, 2009
CD1d-based combination therapy eradicates established tumors in miceMichele W L Teng, Janelle Sharkey, Nicole M McLaughlin, et al.
European Journal of Immunology|December 30, 2009
The A2aR adenosine receptor controls cytokine production in iNKT cellsMichael Nowak, Lydia Lynch, Simon Yue, et al.
Frontiers in Immunology|October 10, 2018
Positive & Negative Roles of Innate Effector Cells in Controlling Cancer ProgressionDorian Stolk, Hans J van der Vliet, Tanja D de Gruijl, et al.
Frontiers in Immunology|May 8, 2026
Physiological, patho-physiological, and potential therapeutic roles for neutrophils in cancer & beyondConnor McGarrity-Cottrell, Aoife McGinley, Natalia Becares, et al.
Clinical Immunology (Orlando, Fla.)|June 2, 2019
Evaluation of the frequency of invariant natural killer T (iNKT) cells in nasal polypsMohammad Fereidouni, Afshin Derakhshani, Simon Yue, et al.
Pageof 8